ArticleThe Lancet. Microbe2021
Surveillance of SARS-CoV-2 in Zimbabwe shows dominance of variants of concern.
Article in The Lancet. Microbe, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Technological Barriers to Routine Genomic Surveillance for Vaccine Development Against SARS-CoV-2 in Africa: A Systematic Review.Influenza and other respiratory viruses · 2024Pooled it
- Article
- Clinical characteristics and outcomes of patients admitted with COVID-19 at a public-sector hospital over the first two waves of SARS-CoV-2 infection in Harare, Zimbabwe: A prospective cohort study.PLOS global public health · 2024Article
- Replacement of the Alpha variant of SARS-CoV-2 by the Delta variant in Lebanon between April and June 2021.Microbial genomics · 2022Article
- Enhancing SARS-CoV-2 surveillance through regular genomic sequencing is an essential element of COVID-19 control in resource-limited settings.The Pan African medical journal · 2022Article
- Inadequate SARS-CoV-2 Genetic Sequencing capacity in Zimbabwe: A call to urgently address this key gap to control current and future waves.IJID regions · 2021Review
- Community SARS-CoV-2 seroprevalence before and after the second wave of SARS-CoV-2 infection in Harare, Zimbabwe.EClinicalMedicine · 2021Article
- Article
- Drivers of the third wave of COVID-19 in Zimbabwe and challenges for control: perspectives and recommendations.The Pan African medical journal · 2021Article
- SARS-CoV-2 in Zimbabwe: milestones and challenges faced towards achieving the expected 60% herd immunity.The Pan African medical journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.